Abstract: Multiple myeloma is a common hematological malignancy. Multiple new drugs have significantly prolonged its overall survival, but patients with multiple myeloma still could not be cured. Immune dysregulation plays a critical role in the pathogenesis and development of multiple myeloma, and immunotheraphies have brought more treatment options for patients. In this review, we elucidated the mechanisms of immunotherapies for multiple myeloma, and reviewed the recent progress of various immunotherapeutic strategies including monoclonal antibodies, chimeric antigen receptor T cells, antibody drug conjugates and bispecific antibodies.